Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Treatment options for patients with poor clopidogrel response.

Roberts DI, Nawarskas JJ.

Cardiol Rev. 2013 Nov-Dec;21(6):309-17. doi: 10.1097/CRD.0b013e3182a72fab. Review.

PMID:
24096929
2.

Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.

Coleman CI, Limone BL.

Am J Cardiol. 2013 Aug 1;112(3):355-62. doi: 10.1016/j.amjcard.2013.03.036. Epub 2013 Apr 27.

PMID:
23631863
3.

New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.

Sinhal AR, Aylward PE.

Clin Ther. 2013 Aug;35(8):1064-8. doi: 10.1016/j.clinthera.2013.07.429. Review.

PMID:
23973039
4.

Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.

Desai NR, Canestaro WJ, Kyrychenko P, Chaplin D, Martell LA, Brennan T, Matlin OS, Choudhry NK.

Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):694-9. doi: 10.1161/CIRCOUTCOMES.113.000321. Epub 2013 Nov 5.

5.
6.

Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.

Norgard NB, Dinicolantonio JJ.

Postgrad Med. 2013 Jul;125(4):91-102. doi: 10.3810/pgm.2013.07.2682. Review.

PMID:
23933898
7.

Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.

Stimpfle F, Karathanos A, Droppa M, Metzger J, Rath D, Müller K, Tavlaki E, Schäffeler E, Winter S, Schwab M, Gawaz M, Geisler T.

Thromb Res. 2014 Jul;134(1):105-10. doi: 10.1016/j.thromres.2014.05.006. Epub 2014 May 10.

PMID:
24856643
8.

[Current options to manage clopidogrel poor responsiveness].

Fileti L, Campo G, Valgimigli M, Marchesini J, Ferrari R.

G Ital Cardiol (Rome). 2010 Dec;11(12):881-9. Review. Italian.

PMID:
21355335
9.

Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.

Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW.

Circulation. 2013 Aug 20;128(8):823-33. doi: 10.1161/CIRCULATIONAHA.113.002303. Epub 2013 Jul 12.

10.

Antiplatelet options for secondary prevention in acute coronary syndromes.

Silvain J, Cayla G, O'Connor SA, Collet JP, Montalescot G.

Expert Rev Cardiovasc Ther. 2011 Nov;9(11):1403-15. doi: 10.1586/erc.11.139. Review.

PMID:
22059790
11.

Prasugrel versus clopidogrel: new management strategies for acute coronary syndrome.

Schnapf AJ.

J Cardiovasc Nurs. 2013 Sep-Oct;28(5):483-94. doi: 10.1097/JCN.0b013e31826173ba.

PMID:
22990232
12.
13.

Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.

Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.

J Am Coll Cardiol. 2012 Jul 17;60(3):193-9. doi: 10.1016/j.jacc.2012.03.050.

14.

Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J.

Med Sci Monit. 2009 Dec;15(12):MS24-30. Review.

PMID:
19946242
15.

Role of phenotypic and genetic testing in managing clopidogrel therapy.

Chan NC, Eikelboom JW, Ginsberg JS, Lauw MN, Vanassche T, Weitz JI, Hirsh J.

Blood. 2014 Jul 31;124(5):689-99. doi: 10.1182/blood-2014-01-512723. Epub 2014 Jun 20. Review.

16.

A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Dasbiswas A, Rao MS, Babu PR, Vijayvergiya R, Nayak R, Dani S, Tyagi S, Hiremath S, Patel T, Alexander T, Prakash VS, Singh DP, Yadav MK, Pathak K, Srivastava A.

J Assoc Physicians India. 2013 Feb;61(2):114-6, 126.

PMID:
24471250
17.

Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.

Behr T, Kuch B, Behr W, von Scheidt W.

Clin Res Cardiol. 2011 Oct;100(10):907-14. doi: 10.1007/s00392-011-0321-4. Epub 2011 Apr 30.

PMID:
21533581
18.

Ticagrelor: a novel reversible oral antiplatelet agent.

Nawarskas JJ, Clark SM.

Cardiol Rev. 2011 Mar-Apr;19(2):95-100. doi: 10.1097/CRD.0b013e3182099d86. Review.

PMID:
21285670
19.

[Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel].

Abbate R, Crea F, De Servi S, Filippi E, Gensini GF, Golinos P, Savonitto S.

G Ital Cardiol (Rome). 2010 Feb;11(2):127-37. Review. Italian.

PMID:
20408476
20.

Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.

Steiner S, Moertl D, Chen L, Coyle D, Wells GA.

Thromb Haemost. 2012 Aug;108(2):318-27. doi: 10.1160/TH11-08-0586. Epub 2012 May 25.

PMID:
22627948
Items per page

Supplemental Content

Write to the Help Desk